Ursula Matulonis1, Ignace Vergote2, Floor Backes3, Lainie P Martin4, Scott McMeekin5, Michael Birrer6, Frank Campana7, Yi Xu7, Coumaran Egile8, Sharad Ghamande9. 1. Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Ursula_Matulonis@dfci.harvard.edu. 2. Leuven Cancer Institute, Leuven, European Union, Belgium. 3. Ohio State University, Columbus, OH, USA. 4. Fox Chase Cancer Center, Philadelphia, PA, USA. 5. University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 6. Massachusetts General Hospital Cancer Center, Boston, MA, USA. 7. Sanofi, Cambridge, MA, USA. 8. Sanofi Oncology, Vitry sur Seine, France. 9. Georgia Regents University Cancer Center, Augusta, GA, USA.
Abstract
OBJECTIVE: Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational treatment options in this setting. This study evaluated the efficacy and safety of the PI3K inhibitor pilaralisib (SAR245408; XL147) in advanced or recurrent endometrial carcinoma. METHODS: This Phase II, multicenter, single-arm, open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma, who had received one or two prior chemotherapy regimens. Patients received pilaralisib 600mg capsules or 400mg tablets once daily. Primary endpoints were objective response rate (ORR), proportion of patients with progression-free survival (PFS) >6months and safety. Molecular profiling in archival tumor tissue and circulating tumor DNA were performed to identify molecular markers associated with response or resistance to pilaralisib. RESULTS: 67 patients were enrolled, of which 50 and 17 patients had received one or two prior regimens, respectively. Complete or partial tumor responses occurred in two patients each (ORR 6.0%); three had tumors with normal PTEN expression and PIK3R1 mutations and one had a tumor with PTEN protein deficiency. However, there was no association between molecular alterations and clinical activity. Rate of PFS>6months was 11.9%. The most commonly reported treatment-related adverse events (AEs) were rash (40.3%), diarrhea (37.3%) and fatigue (28.4%). The most commonly reported treatment-related grade ≥3 AEs were rash (9.0%), diarrhea (4.5%) and increased alanine aminotransferase (4.5%). CONCLUSIONS: Pilaralisib was associated with a favorable safety profile and minimal antitumor activity in advanced or recurrent endometrial carcinoma.
OBJECTIVE:Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational treatment options in this setting. This study evaluated the efficacy and safety of the PI3K inhibitor pilaralisib (SAR245408; XL147) in advanced or recurrent endometrial carcinoma. METHODS: This Phase II, multicenter, single-arm, open-label study enrolled patients with histologically confirmed advanced or recurrent endometrial carcinoma, who had received one or two prior chemotherapy regimens. Patients received pilaralisib 600mg capsules or 400mg tablets once daily. Primary endpoints were objective response rate (ORR), proportion of patients with progression-free survival (PFS) >6months and safety. Molecular profiling in archival tumor tissue and circulating tumor DNA were performed to identify molecular markers associated with response or resistance to pilaralisib. RESULTS: 67 patients were enrolled, of which 50 and 17 patients had received one or two prior regimens, respectively. Complete or partial tumor responses occurred in two patients each (ORR 6.0%); three had tumors with normal PTEN expression and PIK3R1 mutations and one had a tumor with PTEN protein deficiency. However, there was no association between molecular alterations and clinical activity. Rate of PFS>6months was 11.9%. The most commonly reported treatment-related adverse events (AEs) were rash (40.3%), diarrhea (37.3%) and fatigue (28.4%). The most commonly reported treatment-related grade ≥3 AEs were rash (9.0%), diarrhea (4.5%) and increased alanine aminotransferase (4.5%). CONCLUSIONS:Pilaralisib was associated with a favorable safety profile and minimal antitumor activity in advanced or recurrent endometrial carcinoma.
Authors: Panagiotis A Konstantinopoulos; William T Barry; Michael Birrer; Shannon N Westin; Karen A Cadoo; Geoffrey I Shapiro; Erica L Mayer; Roisin E O'Cearbhaill; Robert L Coleman; Bose Kochupurakkal; Christin Whalen; Jennifer Curtis; Sarah Farooq; Weixiu Luo; Julia Eismann; Mary K Buss; Carol Aghajanian; Gordon B Mills; Sangeetha Palakurthi; Paul Kirschmeier; Joyce Liu; Lewis C Cantley; Scott H Kaufmann; Elizabeth M Swisher; Alan D D'Andrea; Eric Winer; Gerburg M Wulf; Ursula A Matulonis Journal: Lancet Oncol Date: 2019-03-14 Impact factor: 41.316
Authors: Vicky Makker; Fernando O Recio; Ling Ma; Ursula A Matulonis; Jennifer O Lauchle; Hema Parmar; Houston N Gilbert; Joseph A Ware; Rui Zhu; Shan Lu; Ling-Yuh Huw; Yulei Wang; Hartmut Koeppen; Jill M Spoerke; Mark R Lackner; Carol A Aghajanian Journal: Cancer Date: 2016-09-07 Impact factor: 6.860
Authors: Rameen Beroukhim; Helga B Salvesen; Frederik Holst; Henrica M J Werner; Siv Mjøs; Erling A Hoivik; Kanthida Kusonmano; Elisabeth Wik; Anna Berg; Even Birkeland; William J Gibson; Mari K Halle; Jone Trovik; Andrew D Cherniack; Karl-Henning Kalland; Gordon B Mills; Christian F Singer; Camilla Krakstad Journal: Clin Cancer Res Date: 2018-11-15 Impact factor: 12.531
Authors: Dejan Juric; Johann S de Bono; Patricia M LoRusso; John Nemunaitis; Elisabeth I Heath; Eunice L Kwak; Teresa Macarulla Mercadé; Elena Geuna; Maria Jose de Miguel-Luken; Chirag Patel; Keisuke Kuida; Serap Sankoh; Eric H Westin; Fabian Zohren; Yaping Shou; Josep Tabernero Journal: Clin Cancer Res Date: 2017-05-10 Impact factor: 12.531
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: U A Matulonis; G M Wulf; W T Barry; M Birrer; S N Westin; S Farooq; K M Bell-McGuinn; E Obermayer; C Whalen; T Spagnoletti; W Luo; H Liu; R C Hok; C Aghajanian; D B Solit; G B Mills; B S Taylor; H Won; M F Berger; S Palakurthi; J Liu; L C Cantley; E Winer Journal: Ann Oncol Date: 2017-03-01 Impact factor: 32.976